Veinway develops advanced tools for venous recanalization, focusing on crossing challenging vein blockages. Their Traversa device is engineered to reliably cross venous occlusions quickly and safely. This technology aims to provide physicians with a dependable solution for previously uncrossable venous obstructions.
Funding
$10.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic venous occlusions, caused by blood clots or disease, can be difficult for physicians to treat due to the challenges in crossing the complete blockage with standard tools. Current methods can be time-consuming and may not always be successful in navigating through hardened or complex venous obstructions.
Solution
VeinWay is developing the Traversa catheter, a specialized device engineered to facilitate the recanalization of chronic venous occlusions. The Traversa is designed to enable physicians to cross previously uncrossable veins in a targeted timeframe of thirty minutes or less. Early data suggests a high safety profile for the device. The device is designed for consistent and reliable performance in treating venous blockages, offering a solution for cases where standard catheters may fail.
Target Audience
The primary users are vascular surgeons, interventional radiologists, and other physicians who specialize in treating venous disease and require advanced tools for recanalizing chronic venous occlusions.
Features
- Designed for rapid crossing of venous occlusions, targeted at 30 minutes or less.
- Engineered for a high degree of safety during recanalization procedures.
- Intended for reliable and consistent performance in crossing challenging venous blockages.